Emmaus Life Sciences, Inc. Common Stock
EMMA
EMMA was delisted on the 10th of September, 2019.
12 hedge funds and large institutions have $198K invested in Emmaus Life Sciences, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
320% more capital invested
Capital invested by funds: $47.1K → $198K (+$151K)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$69.4K |
| 2 |
Jane Street
New York
|
+$42.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.8K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$9.37K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$7.46K |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$647 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $57K | +$69.4K | +5,252 | New |
|
|
CC
2
Cannell & Co
New York
| $36K | – | – | – |
|
|
3
Jane Street
New York
| $35K | +$42.3K | +3,203 | New |
|
|
FFA
4
First Foundation Advisors
Irvine,
California
| $29K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $20K | +$23.8K | +1,800 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $8K | +$7.46K | +565 | +351% |
|
|
PAM
7
Panagora Asset Management
Boston,
Massachusetts
| $8K | +$9.37K | +709 | New |
|
|
HFM
8
Hartford Financial Management
Hartford,
Connecticut
| $5K | – | – | – |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$647 | -49 | -83% |
|
EMMA Hedge Fund Activity: Q2 2018 in Review
12 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Emmaus Life Sciences, Inc. Common Stock (EMMA) for Q2 2018, worth a combined $198K — up 320% from $47.1K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EMMA positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $69.4K. The largest seller was Bank of America, cutting an estimated $647.
- 12 institutional investors held Emmaus Life Sciences, Inc. Common Stock (EMMA) as of Q2 2018, up from 9 in Q1 2018.
- Funds reported $198K of Emmaus Life Sciences, Inc. Common Stock stock for Q2 2018, up 320% quarter-over-quarter.
- 4 funds opened new Emmaus Life Sciences, Inc. Common Stock positions in Q2 2018 and 1 closed out, a net change of +3 holders.
- The largest Emmaus Life Sciences, Inc. Common Stock buyer in Q2 2018 was Susquehanna International Group, an estimated $69.4K added.
- The largest Emmaus Life Sciences, Inc. Common Stock seller in Q2 2018 was Bank of America, an estimated $647 sold.
Based on aggregated 13F filings for Q2 2018.